AGRE to Provide Autism Data through BioDiscovery Platform in Co-marketing Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Bioinformatics firm BioDiscovery and the Autism Genetic Resource Exchange today announced a co-marketing agreement that allows AGRE to provide copy number and allelic event data to its researchers through BioDiscovery's Nexus DB platform.

BioDiscovery's platform is for DNA copy number analysis and integrates and processes data from commercial array platforms as well as custom arrays. AGRE, a program of Autism Speaks, collects and houses genetic and phenotypic data on more than 1,300 families with autism.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.